Ulcerative colitis - Pipeline Review, 2019
FirstView Market Insight "Ulcerative Colitis- Pipeline Review, 2019" provides an overview of the pipeline landscape for Ulcerative Colitis- Pipeline Review, 2019. It provides comprehensive insights of all the clinical and non-clinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc. These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.
Ulcerative colitis (UC) is a disease of colon or large intestine, which leads to inflammation of the colon and development of tiny sores that produce mucous or pus. The disease happens due to dysfunction of immune system. As a result of the response, white blood cells (WBCs) start reaching the large intestine lining, causing inflammation of the colon. Symptoms of the disease include loose or urgent bowel movements, abdominal cramps, bloody stools, and others. Family history is one of the significant risk factors for UC. The disease is non-contagious, whereas the exact reason of the disease is unknown.
There are many treatment options available such as Antibiotics, Aminosalicylates (5-ASAs), Corticosteroids, Immunomodulators, Biologics, other oral agents. Conventional therapies (aminosalicylates, corticosteroids, immunosuppressants) are the first line therapies for the treatment of ulcerative colitis. TNF-? inhibitors remains the mainstream biological therapies for the treatment of Ulcerative colitis. Remicade and Humira remains the major therapies indicated for the treatment of ulcerative colitis. Xeljanz recently got approval from US FDA with a novel mechanism of action has advantage in its oral route of administration. Gilead/Galapagos’s filgotinib and AbbVie’s upadacitinib are other drugs which are expected to enter the market soon and have great credentials to pose a threat to the existing therapies.
Ulcerative colitis (UC) is the most common form of inflammatory bowel disease which affects several people. From a global perspective, several research studies in 2018 have reported annual incidence rates of UC ranging from 0.5 to 24.5 cases per 100,000 people. On the other hand, incidences have been increasing in Asian and South European countries. In the United States, UC affects an estimated 500,000 people and is the cause of 250,000 doctor visits and 30,000 hospitalizations, each year. UC has an uneven presence in major geographical regions across the world.The ulcerative colitis market was valued at USD 6,854.47 million in 2018, and is also expected to register a CAGR of 4.86% during the forecast period (2019-2029).
Ulcerative Proctitis Segment is Expected to Experience the Fastest Growth during the Forecast Period
Ulcerative proctitis is one of the types of ulcerative colitis. It is considered as the initial manifestation of ulcerative colitis, in which fine ulcerations in the inner linings of mucosa of the large intestine are seen. A survey was conducted by NIH in 2016, to understand the prevalence of disease, which gave results, such as 25% of the pediatric patients surveyed had the disease, and 17 to 21% of the adult patients had ulcerative proctitis. As per this data obtained by the survey, NIH stated that there was a rise in the number of patients suffering from ulcerative proctitis, compared to the previous years. Hence, this segment, by disease type, is believed to experience growth in the future.
Report Overview:
This part of report provides detailed description of indication which enables the client to understand the landscape of the Ulcerative colitis disease. This report covers the basic definition, etiology, symptoms, disease progression, treatment guidelines, pathophysiology, methods to diagnose for Ulcerative colitis disease.
Pipeline Overview:
This report provides extensive scenario and growth prospects of the market. This section includes the graphical representations of the future treatment landscape based on various phases of development including the NDA/BLA Filing, Phase III, Phase II, Phase I, Pre-Clinical and the Discovery. It also includes details of products which have been dormant or discontinued during the trial stages of development.
Drug Profile Overview:
The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.
Clinical Trial Overview:
This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.
Product Development Activity:
This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.
Company Overview:
Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial
Scope
Ulcerative colitis (UC) is a disease of colon or large intestine, which leads to inflammation of the colon and development of tiny sores that produce mucous or pus. The disease happens due to dysfunction of immune system. As a result of the response, white blood cells (WBCs) start reaching the large intestine lining, causing inflammation of the colon. Symptoms of the disease include loose or urgent bowel movements, abdominal cramps, bloody stools, and others. Family history is one of the significant risk factors for UC. The disease is non-contagious, whereas the exact reason of the disease is unknown.
There are many treatment options available such as Antibiotics, Aminosalicylates (5-ASAs), Corticosteroids, Immunomodulators, Biologics, other oral agents. Conventional therapies (aminosalicylates, corticosteroids, immunosuppressants) are the first line therapies for the treatment of ulcerative colitis. TNF-? inhibitors remains the mainstream biological therapies for the treatment of Ulcerative colitis. Remicade and Humira remains the major therapies indicated for the treatment of ulcerative colitis. Xeljanz recently got approval from US FDA with a novel mechanism of action has advantage in its oral route of administration. Gilead/Galapagos’s filgotinib and AbbVie’s upadacitinib are other drugs which are expected to enter the market soon and have great credentials to pose a threat to the existing therapies.
Ulcerative colitis (UC) is the most common form of inflammatory bowel disease which affects several people. From a global perspective, several research studies in 2018 have reported annual incidence rates of UC ranging from 0.5 to 24.5 cases per 100,000 people. On the other hand, incidences have been increasing in Asian and South European countries. In the United States, UC affects an estimated 500,000 people and is the cause of 250,000 doctor visits and 30,000 hospitalizations, each year. UC has an uneven presence in major geographical regions across the world.The ulcerative colitis market was valued at USD 6,854.47 million in 2018, and is also expected to register a CAGR of 4.86% during the forecast period (2019-2029).
Ulcerative Proctitis Segment is Expected to Experience the Fastest Growth during the Forecast Period
Ulcerative proctitis is one of the types of ulcerative colitis. It is considered as the initial manifestation of ulcerative colitis, in which fine ulcerations in the inner linings of mucosa of the large intestine are seen. A survey was conducted by NIH in 2016, to understand the prevalence of disease, which gave results, such as 25% of the pediatric patients surveyed had the disease, and 17 to 21% of the adult patients had ulcerative proctitis. As per this data obtained by the survey, NIH stated that there was a rise in the number of patients suffering from ulcerative proctitis, compared to the previous years. Hence, this segment, by disease type, is believed to experience growth in the future.
Report Overview:
This part of report provides detailed description of indication which enables the client to understand the landscape of the Ulcerative colitis disease. This report covers the basic definition, etiology, symptoms, disease progression, treatment guidelines, pathophysiology, methods to diagnose for Ulcerative colitis disease.
Pipeline Overview:
This report provides extensive scenario and growth prospects of the market. This section includes the graphical representations of the future treatment landscape based on various phases of development including the NDA/BLA Filing, Phase III, Phase II, Phase I, Pre-Clinical and the Discovery. It also includes details of products which have been dormant or discontinued during the trial stages of development.
Drug Profile Overview:
The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.
Clinical Trial Overview:
This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.
Product Development Activity:
This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.
Company Overview:
Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial
Scope
- The report provides a competitive landscape of Ulcerative colitis
- The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and end-point status
- The report provides the list of companies which are the most active in the pipeline
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery
- The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action (MoA); route of administration (RoA); Stage of development; clinical trial status; licensing and collaboration details & other developmental activities
- The report features comparative analysis of product profiles based on molecule type; mechanism of action (MoA); route of administration (RoA)
- The report summarizes all the dormant and discontinued pipeline projects
- The report also provides latest news for the past one year
- To identifying prominent players in the Ulcerative colitis treatment landscape
- To determine the drivers; barriers and unmet need in the Ulcerative colitis treatment space
- Gain strategically significant competitor information; analysis; and insights to formulate effective R&D strategies
- Define in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration
1. DISEASE OVERVIEW
1.1. Pathophysiology
1.2. Symptoms
1.3. Etiology
1.4. Diagnosis
1.5. Etiology
1.6. Treatment Algorithm
1.7. Treatment Options
2. FEATURED NEWS AND PRESS RELEASES, 2018-2019
3. LIST OF COMPANIES DEVELOPING ULCERATIVE COLITIS- PIPELINE REVIEW, 2019
4. TREATMENT ALGORITHM
4.1. Drug classes
4.1.1. TNF-Alpha Inhibitor
4.1.2. Cell Adhesion Molecule Inhibitors
4.1.3. Janus-Activated Kinase Inhibitors
4.1.4. Sphingosine-1-Phosphate Receptor Modulators
4.1.5. Aminosalicylates
4.1.6. Corticosteroids
4.1.7. Immunosuppressants
5. CURRENT UNMET NEEDS
6. MARKET TRND:
7. PIPELINE THERAPEUTICS
8. THERAPEUTICS UNDER DEVELOPMENT BY COMPANIES
9. LATE STAGE PRODUCTS (PHASE III)
9.1. Alicaforsen (ICAM-1) Ionis/Atlantic
9.1.1. Product Description
9.1.2. Research and Development
9.1.3. Product Development Activities
9.2. AJM 300 (alpha4 integrin receptor antagonist)
9.2.1. Product Description
9.2.2. Research and Development
9.2.3. Product Development Activities
9.3. Entyvio SC (anti-?4?7 integrin)
9.3.1. Product Description
9.3.2. Research and Development
9.3.3. Product Development Activities
9.4. Etrolizumab (RG7413, anti-?4?7 / ?E?7)
9.4.1. Product Description
9.4.2. Research and Development
9.4.3. Product Development Activities
9.5. Filgotinib (GLPG0634; JAK1)
9.5.1. Product Description
9.5.2. Research and Development
9.5.3. Product Development Activities
9.6. Ozanimod (RPC1063; S1PR1)
9.6.1. Product Description
9.6.2. Research and Development
9.6.3. Product Development Activities
10. MID STAGE PRODUCTS (PHASE II)
10.1. ABI464 (RNA biogenesis)
10.1.1. Product Description
10.1.2. Research and Development
10.1.3. Product Development Activities
10.2. Bimekizumab (UCB-4940; anti-IL-17AF)
10.2.1. Product Description
10.2.2. Research and Development
10.2.3. Product Development Activities
10.3. Brilacidin (antibiotic)
10.3.1. Product Description
10.3.2. Research and Development
10.3.3. Product Development Activities
10.4. DW2007
10.4.1. Product Description
10.4.2. Research and Development
10.4.3. Product Development Activities
10.5. E6007 (integrin)
10.5.1. Product Description
10.5.2. Research and Development
10.5.3. Product Development Activities
10.6. Etrasimod (APD334; S1PR1)
10.6.1. Product Description
10.6.2. Research and Development
10.6.3. Product Development Activities
10.7. INN-108 Product Description
10.7.1. Research and Development
10.7.2. Product Development Activities
10.8. Kappaproct (DIMS 0150; NF-kappa B inhibitor, rectal admin)
10.8.1. Product Description
10.8.2. Research and Development
10.8.3. Product Development Activities
10.9. KHK4083 (anti-OX40)
10.9.1. Product Description
10.9.2. Research and Development
10.9.3. Product Development Activities
10.10. OPRX-106 (TNF?)
10.10.1. Product Description
10.10.2. Research and Development
10.10.3. Product Development Activities
10.11. PF-06480605 (anti-TL1A)
10.11.1. Product Description
10.11.2. Research and Development
10.11.3. Product Development Activities
10.12. PF-06651600 (JAK3)
10.12.1. Product Description
10.12.2. Research and Development
10.12.3. Product Development Activities
10.13. Otzela (PDE4)
10.13.1. Product Description
10.13.2. Research and Development
10.13.3. Product Development Activities
11. EARLY STAGE PRODUCTS (PHASE I AND IND)
11.1. Bepecin (pentadecapeptide)
11.1.1. Product Description
11.1.2. Research and Development
11.1.3. Product Development Activities
11.2. BMS-986184 (anti-CSCL10 / IP10)
11.2.1. Product Description
11.2.2. Research and Development
11.2.3. Product Development Activities
11.3. Dolcanatide (SP 333; guanylate cyclase-C agonist)
11.3.1. Product Description
11.3.2. Research and Development
11.3.3. Product Development Activities
11.4. KAG-308 (prostaglandin-E-EP4 receptor agonist)
11.4.1. Product Description
11.4.2. Research and Development
11.4.3. Product Development Activities
11.5. RG 7880 (anti-IL-22)
11.5.1. Product Description
11.5.2. Research and Development
11.5.3. Product Development Activities
11.6. TD-1473 (GI-targeted pan-JAK)
11.6.1. Product Description
11.6.2. Research and Development
11.6.3. Product Development Activities
11.7. AVX-740 (oral TNF)
11.7.1. Product Description
11.7.2. Research and Development
11.7.3. Product Development Activities
11.8. GSK 2245840 (SRT 2104, SIRT1 activator)
11.8.1. Product Description
11.8.2. Research and Development
11.8.3. Product Development Activities
12. PRE-CLINICAL AND DISCOVERY PRODUCTS
12.1. LY 3207447
12.1.1. Product Description
12.1.2. Research and Development
12.1.3. Product Development Activities
12.2. ABP 201
12.2.1. Product Description
12.2.2. Research and Development
12.2.3. Product Development Activities
13. DRIVERS OF ULCERATIVE COLITIS - PIPELINE REVIEW, 2019
14. CONSTRAINTS OF ULCERATIVE COLITIS PIPELINE REVIEW, 2019
15. THERAPEUTIC ASSESSMENT
15.1. Assessment by Route of Administration
15.2. Assessment by Phase & Route of Administration
15.3. Assessment by Molecule Type
15.4. Assessment by Phase & Molecule type
15.5. Assessment by Target
15.6. Assessment by Mechanism of Action
16. COLLABORATIONS AND ACQUISITIONS DETAILS
17. DORMANT PRODUCTS
18. DISCONTINUED PRODUCTS
19. MARKET TRENDS
20. MARKET OPPORTUNITY ASSESSMENT
21. UNMET NEEDS
22. SWOT ANALYSIS
23. APPENDIX
24. REPORT METHODOLOGY
25. CONSULTING SERVICES
26. DISCLAIMER
1.1. Pathophysiology
1.2. Symptoms
1.3. Etiology
1.4. Diagnosis
1.5. Etiology
1.6. Treatment Algorithm
1.7. Treatment Options
2. FEATURED NEWS AND PRESS RELEASES, 2018-2019
3. LIST OF COMPANIES DEVELOPING ULCERATIVE COLITIS- PIPELINE REVIEW, 2019
4. TREATMENT ALGORITHM
4.1. Drug classes
4.1.1. TNF-Alpha Inhibitor
4.1.2. Cell Adhesion Molecule Inhibitors
4.1.3. Janus-Activated Kinase Inhibitors
4.1.4. Sphingosine-1-Phosphate Receptor Modulators
4.1.5. Aminosalicylates
4.1.6. Corticosteroids
4.1.7. Immunosuppressants
5. CURRENT UNMET NEEDS
6. MARKET TRND:
7. PIPELINE THERAPEUTICS
8. THERAPEUTICS UNDER DEVELOPMENT BY COMPANIES
9. LATE STAGE PRODUCTS (PHASE III)
9.1. Alicaforsen (ICAM-1) Ionis/Atlantic
9.1.1. Product Description
9.1.2. Research and Development
9.1.3. Product Development Activities
9.2. AJM 300 (alpha4 integrin receptor antagonist)
9.2.1. Product Description
9.2.2. Research and Development
9.2.3. Product Development Activities
9.3. Entyvio SC (anti-?4?7 integrin)
9.3.1. Product Description
9.3.2. Research and Development
9.3.3. Product Development Activities
9.4. Etrolizumab (RG7413, anti-?4?7 / ?E?7)
9.4.1. Product Description
9.4.2. Research and Development
9.4.3. Product Development Activities
9.5. Filgotinib (GLPG0634; JAK1)
9.5.1. Product Description
9.5.2. Research and Development
9.5.3. Product Development Activities
9.6. Ozanimod (RPC1063; S1PR1)
9.6.1. Product Description
9.6.2. Research and Development
9.6.3. Product Development Activities
10. MID STAGE PRODUCTS (PHASE II)
10.1. ABI464 (RNA biogenesis)
10.1.1. Product Description
10.1.2. Research and Development
10.1.3. Product Development Activities
10.2. Bimekizumab (UCB-4940; anti-IL-17AF)
10.2.1. Product Description
10.2.2. Research and Development
10.2.3. Product Development Activities
10.3. Brilacidin (antibiotic)
10.3.1. Product Description
10.3.2. Research and Development
10.3.3. Product Development Activities
10.4. DW2007
10.4.1. Product Description
10.4.2. Research and Development
10.4.3. Product Development Activities
10.5. E6007 (integrin)
10.5.1. Product Description
10.5.2. Research and Development
10.5.3. Product Development Activities
10.6. Etrasimod (APD334; S1PR1)
10.6.1. Product Description
10.6.2. Research and Development
10.6.3. Product Development Activities
10.7. INN-108 Product Description
10.7.1. Research and Development
10.7.2. Product Development Activities
10.8. Kappaproct (DIMS 0150; NF-kappa B inhibitor, rectal admin)
10.8.1. Product Description
10.8.2. Research and Development
10.8.3. Product Development Activities
10.9. KHK4083 (anti-OX40)
10.9.1. Product Description
10.9.2. Research and Development
10.9.3. Product Development Activities
10.10. OPRX-106 (TNF?)
10.10.1. Product Description
10.10.2. Research and Development
10.10.3. Product Development Activities
10.11. PF-06480605 (anti-TL1A)
10.11.1. Product Description
10.11.2. Research and Development
10.11.3. Product Development Activities
10.12. PF-06651600 (JAK3)
10.12.1. Product Description
10.12.2. Research and Development
10.12.3. Product Development Activities
10.13. Otzela (PDE4)
10.13.1. Product Description
10.13.2. Research and Development
10.13.3. Product Development Activities
11. EARLY STAGE PRODUCTS (PHASE I AND IND)
11.1. Bepecin (pentadecapeptide)
11.1.1. Product Description
11.1.2. Research and Development
11.1.3. Product Development Activities
11.2. BMS-986184 (anti-CSCL10 / IP10)
11.2.1. Product Description
11.2.2. Research and Development
11.2.3. Product Development Activities
11.3. Dolcanatide (SP 333; guanylate cyclase-C agonist)
11.3.1. Product Description
11.3.2. Research and Development
11.3.3. Product Development Activities
11.4. KAG-308 (prostaglandin-E-EP4 receptor agonist)
11.4.1. Product Description
11.4.2. Research and Development
11.4.3. Product Development Activities
11.5. RG 7880 (anti-IL-22)
11.5.1. Product Description
11.5.2. Research and Development
11.5.3. Product Development Activities
11.6. TD-1473 (GI-targeted pan-JAK)
11.6.1. Product Description
11.6.2. Research and Development
11.6.3. Product Development Activities
11.7. AVX-740 (oral TNF)
11.7.1. Product Description
11.7.2. Research and Development
11.7.3. Product Development Activities
11.8. GSK 2245840 (SRT 2104, SIRT1 activator)
11.8.1. Product Description
11.8.2. Research and Development
11.8.3. Product Development Activities
12. PRE-CLINICAL AND DISCOVERY PRODUCTS
12.1. LY 3207447
12.1.1. Product Description
12.1.2. Research and Development
12.1.3. Product Development Activities
12.2. ABP 201
12.2.1. Product Description
12.2.2. Research and Development
12.2.3. Product Development Activities
13. DRIVERS OF ULCERATIVE COLITIS - PIPELINE REVIEW, 2019
14. CONSTRAINTS OF ULCERATIVE COLITIS PIPELINE REVIEW, 2019
15. THERAPEUTIC ASSESSMENT
15.1. Assessment by Route of Administration
15.2. Assessment by Phase & Route of Administration
15.3. Assessment by Molecule Type
15.4. Assessment by Phase & Molecule type
15.5. Assessment by Target
15.6. Assessment by Mechanism of Action
16. COLLABORATIONS AND ACQUISITIONS DETAILS
17. DORMANT PRODUCTS
18. DISCONTINUED PRODUCTS
19. MARKET TRENDS
20. MARKET OPPORTUNITY ASSESSMENT
21. UNMET NEEDS
22. SWOT ANALYSIS
23. APPENDIX
24. REPORT METHODOLOGY
25. CONSULTING SERVICES
26. DISCLAIMER
LIST OF TABLES
Table 1: Marketed and Pipeline Ulcerative Colitis- Pipeline Review, 2019 drugs, 2019
Table 2: Sales of Marketed drugs, 2019
Table 3: Patent expiration details – marketed drugs, 2019
Table 4: Number of Products Under Development for Ulcerative Colitis- Pipeline Review, 2019, 2019
Table 5: Products under Development by Companies, 2019
Table 6: Late Stage Products, 2019
Table 7: Mid Stage Products, 2019
Table 8: Early Stage Products, 2019
Table 9: Pre-Clinical and Discovery Products, 2019
Table 10: Assessment by Route of Administration, 2019
Table 11: Assessment by Stage and Route of Administration, 2019
Table 12: Assessment by Molecule Type, 2019
Table 13: Assessment by Stage and Molecule Type, 2019
Table 14: Assessment by Target, 2019
Table 15: Assessment by Mechanism of Action, 2019
Table 16: Dormant Products, 2019
Table 17: Discontinued Products, 2019
Table 1: Marketed and Pipeline Ulcerative Colitis- Pipeline Review, 2019 drugs, 2019
Table 2: Sales of Marketed drugs, 2019
Table 3: Patent expiration details – marketed drugs, 2019
Table 4: Number of Products Under Development for Ulcerative Colitis- Pipeline Review, 2019, 2019
Table 5: Products under Development by Companies, 2019
Table 6: Late Stage Products, 2019
Table 7: Mid Stage Products, 2019
Table 8: Early Stage Products, 2019
Table 9: Pre-Clinical and Discovery Products, 2019
Table 10: Assessment by Route of Administration, 2019
Table 11: Assessment by Stage and Route of Administration, 2019
Table 12: Assessment by Molecule Type, 2019
Table 13: Assessment by Stage and Molecule Type, 2019
Table 14: Assessment by Target, 2019
Table 15: Assessment by Mechanism of Action, 2019
Table 16: Dormant Products, 2019
Table 17: Discontinued Products, 2019
LIST OF FIGURES
Figure 1: Marketed and Pipeline Ulcerative Colitis- Pipeline Review, 2019 drugs, 2019
Figure 2: Sales of Marketed drugs, 2019
Figure 3: Patent expiration details – marketed drugs, 2019
Figure 4: Number of Products Under Development for Ulcerative Colitis- Pipeline Review, 2019, 2019
Figure 5: Products under Development by Companies, 2019
Figure 6: Late Stage Products, 2019
Figure 7: Mid Stage Products, 2019
Figure 8: Early Stage Products, 2019
Figure 9: Pre-Clinical and Discovery Products, 2019
Figure 10: Assessment by Route of Administration, 2019
Figure 11: Assessment by Stage and Route of Administration, 2019
Figure 12: Assessment by Molecule Type, 2019
Figure 13: Assessment by Stage and Molecule Type, 2019
Figure 14: Assessment by Target, 2019
Figure 15: Assessment by Mechanism of Action, 2019
Figure 16: Dormant Products, 2019
Figure 17: Discontinued Products, 2019
Figure 1: Marketed and Pipeline Ulcerative Colitis- Pipeline Review, 2019 drugs, 2019
Figure 2: Sales of Marketed drugs, 2019
Figure 3: Patent expiration details – marketed drugs, 2019
Figure 4: Number of Products Under Development for Ulcerative Colitis- Pipeline Review, 2019, 2019
Figure 5: Products under Development by Companies, 2019
Figure 6: Late Stage Products, 2019
Figure 7: Mid Stage Products, 2019
Figure 8: Early Stage Products, 2019
Figure 9: Pre-Clinical and Discovery Products, 2019
Figure 10: Assessment by Route of Administration, 2019
Figure 11: Assessment by Stage and Route of Administration, 2019
Figure 12: Assessment by Molecule Type, 2019
Figure 13: Assessment by Stage and Molecule Type, 2019
Figure 14: Assessment by Target, 2019
Figure 15: Assessment by Mechanism of Action, 2019
Figure 16: Dormant Products, 2019
Figure 17: Discontinued Products, 2019
